GENOTYPING OF DRUG-RESISTANT MYCOBACTERIUM TUBERCULOSIS ISOLATES FROM SOUTHERN KAZAKHSTAN
Main Article Content
Authors
P. Tarlykov
National Center for Biotechnology, 13/5, Korgalzhyn road, Astana, 010000, Kazakhstan
S. Atavliyeva
National Center for Biotechnology, 13/5, Korgalzhyn road, Astana, 010000, Kazakhstan
A. Alenova
National Scientific Center of Phthisiopulmonology, 5 Bekkhozhin str., Almaty, 050010, Kazakhstan
E. Zholdybayeva
National Center for Biotechnology, 13/5, Korgalzhyn road, Astana, 010000, Kazakhstan
Ye. Ramankulov
National Center for Biotechnology, 13/5, Korgalzhyn road, Astana, 010000, Kazakhstan
Abstract
The incidence of drug-resistant tuberculosis in Kazakhstan has risen over the last decades, making it a serious threat. The purpose of this study was to characterize M. tuberculosis isolates circulating in the south of Kazakhstan, based on mutations of known association with multidrug-resistance and extensive drug resistance. A total of 58 clinical isolates of M. tuberculosis with drug resistance from southern Kazakhstan were selected. Seven genetic loci were sequenced, namely, rpoB (for resistance to RIF), katG, inhA (for resistance to INH), embB (for resistance to EMB), as well as the gyrA, gyrB (for resistance to CIP and OFX) and rrs (for resistance to KAN, AMK, and CPR). In addition, mutations in codon 315 of katG (n = 53; 91.4%), in codon 531 of the rpoB (n = 45; 77.6%), at the position of 1401 A/G of rrs (n = 33; 56.9%) and in the codon 94 of the gyrA were found to be prevalent in the samples. MIRU-VNTR typing showed that most isolates belong to the Beijing family (n = 53; 94.4%). Whole genome sequencing of a single M. tuberculosis strain from southern Kazakhstan was conducted. The emergence of drug-resistance is characteristic of the Beijing family, which may explain the increase in the incidence rates of resistant forms of tuberculosis in Kazakhstan.
Keywords
Mycobacterium tuberculosis, WGS, antibiotic resistance, genotyping, MIRU-VNTR
Article Details
References
Global tuberculosis report 2018. World Health Organization. ‒ 2018. ‒ URL: URL.
Bumburidi E., Ajeilat S., Dadu A. et al. Progress toward tuberculosis control and determinants of treatment outcomes--Kazakhstan, 2000-2002. MMWR supplements, 2006, vol. 55, no. 1, pp. 11-15.
Favorov M., Belilovsky E., Aitmagambetova I. et al. Tuberculosis deaths averted by implementation of the DOTS strategy in Kazakhstan. International Journal of Tuberculosis and Lung Disease, 2010, vol. 14, no. 12, pp. 1582-1588.
Davis A., Terlikbayeva A., Aifah A. et al. Risks for tuberculosis in Kazakhstan: implications for prevention. International Journal of Tuberculosis and Lung Disease, 2017, vol. 21, no. 1, pp. 86-92. doi: 10.5588/ijtld.15.0838.
Rios M., Monleon-Getino T. A graphical study of tuberculosis incidence and trends in the WHO's European region (1980-2006). European Journal of Epidemiology, 2009, vol. 24, no. 7, pp. 381-387. doi: 10.1007/s10654-009-9347-6.
Ahmad S., Mokaddas E. Contribution of AGC to ACC and other mutations at codon 315 of the katG gene in isoniazid-resistant Mycobacterium tuberculosis isolates from the Middle East. Int J Antimicrob Agents, 2004, vol. 23, no. 5, pp. 473-479. doi: 10.1016/j.ijantimicag.2003.10.004.
Takiff H.E., Salazar L., Guerrero C. et al. Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. Antimicrob Agents Chemother, 1994, vol. 38, no. 4, pp. 773-780.
Feuerriegel S., Schleusener V., Beckert P. et al. PhyResSE: a Web Tool Delineating Mycobacterium tuberculosis Antibiotic Resistance and Lineage from Whole-Genome Sequencing Data. J Clin Microbiol, 2015, vol. 53, no. 6, pp. 1908-1914. doi: 10.1128/jcm.00025-15.
Feuerriegel S., Koser C.U., Niemann S. Phylogenetic polymorphisms in antibiotic resistance genes of the Mycobacterium tuberculosis complex. J Antimicrob Chemother, 2014, vol. 69, no. 5, pp. 1205-1210. doi: 10.1093/jac/dkt535.
Allix C., Supply P., Fauville-Dufaux M. Utility of fast mycobacterial interspersed repetitive unit-variable number tandem repeat genotyping in clinical mycobacteriological analysis. Clin Infect Dis, 2004, vol. 39, no. 6, pp. 783-789. doi: 10.1086/423383.
Drobniewski F., Balabanova Y., Ruddy M. et al. Rifampin- and multidrug-resistant tuberculosis in Russian civilians and prison inmates: dominance of the beijing strain family. Emerg Infect Dis, 2002, vol. 8, no. 11, pp. 1320-1326. doi: 10.3201/eid0811.020507.
Dymova M.A., Cherednichenko A.G., Alkhovik O.I. et al. Characterization of extensively drug-resistant Mycobacterium tuberculosis isolates circulating in Siberia. BMC Infect Dis, 2014, vol. 14, no. 478, pp. 1471-2334.
Kubica T., Agzamova R., Wright A. et al. The Beijing genotype is a major cause of drug-resistant tuberculosis in Kazakhstan. Int J Tuberc Lung Dis, 2005, vol. 9, no. 6, pp. 646-653.
Mokrousov I. Molecular structure of Mycobacterium tuberculosis population in Russia and its interaction with neighboring countries. Int J Mycobacteriol, 2015, vol. 1, no., pp. 56-57.
Skiba Y., Mokrousov I., Ismagulova G. et al. Molecular snapshot of Mycobacterium tuberculosis population in Kazakhstan: a country-wide study. Tuberculosis, 2015, vol. 95, no. 5, pp. 538-546.
Campbell P.J., Morlock G.P., Sikes R.D. et al. Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis. Antimicrob Agents Chemother, 2011, vol. 55, no. 5, pp. 2032-2041. doi: 10.1128/aac.01550-10.
Feuerriegel S., Oberhauser B., George A.G. et al. Sequence analysis for detection of first-line drug resistance in Mycobacterium tuberculosis strains from a high-incidence setting. BMC Microbiol, 2012, vol. 12, no., pp. 90. doi: 10.1186/1471-2180-12-90.
Marttila H.J., Soini H., Huovinen P. et al. katG mutations in isoniazid-resistant Mycobacterium tuberculosis isolates recovered from Finnish patients. Antimicrob Agents Chemother, 1996, vol. 40, no. 9, pp. 2187-2189.
Scorpio A., Lindholm-Levy P., Heifets L. et al. Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother, 1997, vol. 41, no. 3, pp. 540-543.